12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder — Dan Joseph Stein (2018) | RDL Network
12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder
Dan Joseph Stein, Antti Ahokas, Marek Jarema, А С Аведисова, L. Vavrušová, Олег Чабан, C. Gruget, Valérie Olivier, F. Picarel-Blanchot, Christian de Bodinat
Dan Joseph Stein, Jon‐Paul Khoo, D.M. Van Ameringen, Cyril Höschl, Antti Ahokas, Max Bauer, István Bitter, Marek Jarema, S.N. Mosolov, L. Vavrušová, F. Picarel-Blanchot, Sophie Matharan, Valérie Olivier
Dan Joseph Stein, Antti Ahokas, Marek Jarema, А С Аведисова, L. Vavrušová, Олег Чабан, Valérie Olivier, C. Gruget, F. Picarel-Blanchot, Christian de Bodinat
Discussion(0)
No comments yet. Be the first to comment.